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immediate in situ optical detection of live bacteria
in human alveolar lung tissue†
Ahsan R. Akram,‡a Nicolaos Avlonitis,‡b Annamaria Lilienkampf,b Ana M. Perez-
Lopez,b Neil McDonald,a Sunay V. Chankeshwara,b Emma Scholeﬁeld,a
Christopher Haslett,a Mark Bradley*b and Kevin Dhaliwal*a
The in situ immediate detection of the presence of bacteria in the distal human lung is of signiﬁcant clinical
utility. Herein we describe the development and optimization of a bacterial binding fragment (UBI29–41) of
the antimicrobial peptide, ubiquicidin (UBI), conjugated to an environmentally sensitive ﬂuorophore to
enable rapid live bacterial imaging within human lung tissue. UBI29–41 was modiﬁed for stability in the
presence of human lung bronchoalveolar lavage ﬂuid, for aﬃnity to bacterial membranes and
functionality in human lung tissue. The optimized cyclic structure yields an optical molecular Smartprobe
for bacterial detection in human lung tissue.Introduction
It is a global priority to reduce antibiotic resistance,1 and
consequently novel methodologies to rapidly diagnose or
exclude bacterial infection are urgently required to imple-
ment antibiotic stewardship. Current diagnostic approaches
rely on detecting the non-specic clinical features of a
developing infection alongside optimal sampling of an
aﬀected area and subsequent bacterial culture. However,
these approaches are slow, prone to contamination
and diagnose infection at a late stage. Hence, rapid, sensi-
tive and in situ molecular imaging assays for bacterial
infections address an unmet need for bacterial diagnostics2
and have the potential to lead to more eﬀective antibiotic
prescribing.
Pneumonia is an important clinical disease in which to
develop and apply bacterial diagnostics. It is the leading infec-
tious cause of mortality in children,3 adults admitted to hospital
with pneumonia have a mortality of up to 14%,4 and in critically
ill individuals in the intensive care unit (ICU), those who
develop ventilator associated pneumonia (VAP) can have an
attributable mortality of over 70% with some etiologies.5 During
the development of pneumonia, bacteria proliferate within theGroup, MRC Centre for Inammation
te, 47 Little France Crescent, Edinburgh,
.uk
hool of Chemistry, Joseph Black Building,
E-mail: mark.bradley@ed.ac.uk
ESI) available: Experimental details and
Chemistry 2015distal gas exchanging units of the human lung, an anatomical
region in humans that is considered to be relatively sterile at
basal microbiota levels. This is in contrast to other areas of the
human body where bacterial burden from colonisation is high,
such as the upper airway and gut, where distinguishing colo-
nisation from pathogenic bacteria is a diagnostic challenge.
Indeed current methodologies to diagnose pneumonia rely
upon general sampling from upper airways and are prone to
contamination and consequent ‘false-positive’ initiation of
antibiotic therapy.
Optical molecular imaging (OMI), is a relatively novel
diagnostic approach that has utility in preclinical and clinical
applications.6 Advantages of OMI include: (i) real-time
imaging, (ii) high resolution, (iii) absence of radiation-related
risks and (iv) low costs. However, whilst the applications of
molecular imaging are showing increasing utility in disease
areas such as oncology, there are a limited number of func-
tional eﬀective molecular imaging approaches for bacterial
detection.7
A rational and accepted approach for targeted bacterial
molecular imaging has been to label antimicrobial peptides
(AMPs), widespread components of the innate immune
systems of virtually all multicellular organisms.8 AMPs
possess a number of factors making them promising tools for
bacterial OMI including their amino acid composition,
amphipathicity and cationic charge that enable selective
insertion and binding to the bacterial membrane.9 The most
studied AMP for infection imaging is the 59 amino acid
cationic AMP, ubiquicidin (UBI) and in particular a UBI
fragment containing thirteen amino acid residues (UBI29–41)
[Thr-Gly-Arg-Ala-Lys-Arg-Arg-Met-Gln-Tyr-Asn-Arg-Arg] which
has been utilised in radionucleotide based imaging.10Chem. Sci.
Chemical Science Edge Article
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View Article OnlineHowever its use involves unavoidable radiation exposure and
is not suitable where portable solutions are required, such as
critically ill ventilated patients with suspected pneumonia.
More recently a near-infrared labelled version of UBI29–41
was applied in a murine model of bacterial infection.11
Unfortunately, the synthetic route led to a multitude of
products with the dye dominating the distribution of the
construct, resulting in a similar distribution for the dye
alone compared to the uorescently labelled UBI29–41. In
addition there are obvious “Achilles heels” in a labelled
UBI29–41 peptide with respect to potential degradation
in vivo, exacerbated even more so in sites of activeTable 1 Peptide sequences of compounds synthesised with description
Compound code Modication Pe
UBI-1 UBI29–41 sequence labelled
with carboxyuorescein at
the amino-terminus
FA
Ar
Ar
UBI-2 Fluorophore change to
NBD
NB
Ar
Ar
UBI-3 Norleucine substitution of
methionine to improve
chemical stability
NB
Ar
Ar
UBI-4 N-Methylarginine (MeArg)
insertion based on MALDI-
TOF analysis of cleavage
peptides
NB
M
As
UBI-5 D-Amino acids (D-Val and D-
Phe) incorporated at the C-
terminus to limit
proteolytic degradation
NB
Ar
Ar
UBI-6 PEG insertion at the N and
C-termini
M
Ar
Ty
UBI-7 PEG introduction at the C-
terminus
NB
Ar
Ar
UBI-8 The all D-amino acid
variant of UBI with the
incorporation of D-Nle and
a PEG spacer at the amino
terminus
NB
Al
Gl
OH
UBI-9 Retroinverse sequence of
UBI (all D-amino acids) and
NBD attached to the C-
terminal amino acid.
Peptide capped at the
amino terminus with MeO-
PEG
M
Ty
Ly
Ly
UBI-10* Side-chain to tail
cyclisation of UBI with Met
to Nle substitution
NB
Ar
Ty
UBI-11* As in UBI-10 – a cyclic UBI
with Met to Nle
substitution and insertion
of N-MeArg at the major
cleavage site
NB
Ar
Ty
a Ahx: 6-aminohexanoic acid, PEG: 8-amino-3,6-dioxaoctanoic acid, MeO
amide, NBD: 7-nitrobenz-2-oxa-1,3-diazole, MeArg: N-methyl-arginine, AR
prex D. *A lysine reside was added to the amino terminus of UBI to ena
Chem. Sci.inammation by proteolysis and oxidation. Building on
these developments and also in recognition of the feasibility
of developing an OMI agent (Smartprobe) based upon a UBI
scaﬀold, we embarked upon a lead optimisation approach to
yield a Smartprobe suitable for application in diagnosing
pneumonia (bacterial infection in the distal lung) when
partnered with an optical imaging device. For this Smartp-
robe to be valuable bio-medically we optimised a series of
prerequisites including;
(i) Specicity and selectivity to label clinically relevant
bacteria,
(ii) High signal-to-noise contrast,of modiﬁcationa
ptide sequence Eﬀect on stability and eﬃcacy
M-Ahx-Thr-Gly-Arg-Ala-Lys-
g-Arg-Met-Gln-Tyr-Asn-Arg-
g-NH2
Insuﬃcient signal-to-noise
D-Ahx-Thr-Gly-Arg-Ala-Lys-
g-Arg-Met-Gln-Tyr-Asn-Arg-
g-NH2
Unstable at 37 C in PBS
D-Ahx-Thr-Gly-Arg-Ala-Lys-
g-Arg-Nle-Gln-Tyr-Asn-Arg-
g-NH2
Unstable in ARDS BALF
D-Ahx-Thr-Gly-Arg-Ala-Lys-
eArg-MeArg-Nle-Gln-Tyr-
n-MeArg-MeArg-NH2
Stable in ARDS BALF, poor
bacterial aﬃnity
D-Ahx-Thr-Gly-Arg-Ala-Lys-
g-MeArg-Nle-Gln-Tyr-Asn-
g-Arg-D-Phe-D-Val-NH2
Stable in ARDS BALF, poor
bacterial aﬃnity
eO-PEG-Lys(NBD)-Thr-Gly-
g-Ala-Lys-Arg-Arg-Nle-Gln-
r-Asn-Arg-Arg-PEG-PEG-NH2
Unstable in ARDS BALF, loss
of labelling eﬃcacy
D-Ahx-Thr-Gly-Arg-Ala-Lys-
g-Arg-Nle-Gln-Tyr-Asn-Arg-
g-PEG-PEG-NH2
Unstable in ARDS BALF at 30
minutes, loss of labelling
eﬃcacy
D-PEG-D-Thr-Gly-D-Arg-D-
a-D-Lys-D-Arg-D-Arg-D-Nle-D-
n-D-Tyr-D-Asn-D-Arg-D-Arg-
Stable in ARDS BALF, loss of
labelling eﬃcacy
eO-PEG-D-Arg-D-Arg-D-Asn-D-
r-D-Gln-D-Nle-D-Arg-D-Arg-D-
s-D-Ala-D-Arg-Gly-D-Thr-
s(NBD)-OH
Stable in ARDS BALF, loss of
labelling eﬃcacy
D-Ahx-cyclo[Lys-Thr-Gly-
g-Ala-Lys-Arg-Arg-Nle-Gln-
r-Asn-Arg-Arg-Gly]
Improved stability in ARDS
BALF, improved bacterial
labelling
D-Ahx-cyclo[Lys-Thr-Gly-
g-Ala-Lys-Arg-Arg-Nle-Gln-
r-Asn-Arg-MeArg-Gly]
Stable in ARDS BALF,
reduction of labelling eﬃcacy
PEG: 8-methoxy-3,6-dioxaoctanoic acid, FAM: 5(6)-carboxyuorescein
DS: acute respiratory distress syndrome. All D-amino acid denoted by
ble cyclisation.
This journal is © The Royal Society of Chemistry 2015
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View Article Online(iii) Resistance to degradation and stability in the presence
of human lung bronchoalveolar lavage uid (BALF) from
patients with acute respiratory distress syndrome (ARDS),
(iv) High aﬃnity and bacterial detection by a clinically
approved optical imaging device in human lung alveolar
tissue.
We demonstrate the development and optimisation of
uorescently labelled UBI29–41, through sequential
modication of the uorophore label, peptide sequenceFig. 2 UBI-2 is unstable at 37 C. HPLC chromatograms (gradient aceto
over 10min, then isocratic for 4 min; detection at 380 nm). UBI-2 (1 mgm
(A) day 0 and (B) day 3 after incubation at 37 C.
Fig. 1 NBD–UBI enables live confocal imaging of bacteria. UBI-2 demo
imaged via confocal microscopy. Upper three panels showing UBI-1 (10
P. aeruginosa. Panel insets show cross section of a single bacterium with
and the counterstain in red, demonstrating ﬂuorescence of UBI-2 but n
This journal is © The Royal Society of Chemistry 2015and secondary structure, and demonstrate the ability of
the lead compound to detect live bacteria in human lung
tissue.Results and discussion
We synthesised a series of UBI peptides to assess structure and
functional consequences for bacterial labelling (Table 1) and to
remove proteolytic susceptibilities.nitrile + 0.1% formic acid/water + 0.1% formic acid from 5/95 to 95/5
L1 in PBS, upper panels) and UBI-3 (1 mgmL1 in PBS, lower panels) at
nstrates higher signal to noise for bacterial labelling over UBI-1 when
mM) with P. aeruginosa; lower panel demonstrates UBI-2 (10 mM) with
a plot proﬁle (right of main panel) across the FAM/NBD image in green
ot UBI-1 across the bacteria scale bar ¼ 5 mm.
Chem. Sci.
Fig. 3 UBI-3 retains speciﬁcity and sensitivity for bacterial labelling. (A) Methionine (UBI-2) and norleucine (UBI-3) variants label bacteria with the
same ﬂuorescence intensity. Panels show bacteria labelled with either UBI-2 or UBI-3 with quantiﬁcation of ﬂuorescence (values normalised to
UBI-2) (Bars represent mean, error bars represent standard error of mean, n$ 3, ns ¼ not signiﬁcant, scale bar ¼ 10 mm). (B) Quantiﬁcation from
confocal images of UBI-3 (10 mM) imaging a panel of bacteria (statistical analyses shown compared to unlabelled bacteria, n$ 3 for each bacteria,
*** ¼ p < 0.001). (C) UBI-3; labels bacteria but not isolated human neutrophils (blue arrows). Dotted box enlarged in lower panel and line plot of
ﬂuorescence from green channel shown with yellow representing background, red indicating neutrophil area and blue representing single
bacteria demonstrating labelling of bacteria but not neutrophils, scale bar ¼ 10 mm. [MRSA: methicillin-resistant Staphylococcus aureus, MSSA:
methicillin-sensitive Staphylococcus aureus].
Chem. Sci. This journal is © The Royal Society of Chemistry 2015
Chemical Science Edge Article
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View Article Online
Fig. 4 Reduction of ﬂuorescent intensity of P. aeruginosa labelled
with UBI-3 in the presence of human ARDS BALF. Representative
images of P. aeruginosa imaged with UBI-3 (10 mM) by confocal
microscopy in the presence of phosphate buﬀered saline (PBS) or
ARDS BALF. Quantiﬁcation of ﬂuorescence intensity demonstrating
signiﬁcantly reduced intensity when compared to PBS (bars represent
mean (SEM), n ¼ 3 for PBS and n ¼ 5 for ARDS, ***¼ p < 0.001, scale
bar ¼ 10 mm).
Fig. 6 Confocal Images of compounds UBI-3 to 9 with quantiﬁed
ﬂuorescence. Panels show methicillin-sensitive Staphylococcus
aureus incubated with UBI-3 to 9 (all 10 mM) with quantiﬁcation of
bacterial ﬂuorescence normalized to UBI-3 (bars represent mean
(SEM), n$ 3, ns ¼ not signiﬁcant, *** ¼ p < 0.001, * ¼ p < 0.05, scale
bar ¼ 10 mm).
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View Article Online7-Nitrobenz-2-oxa-1,3-diazole (NBD) demonstrates increased
signal to noise over carboxyuorescein (FAM) UBI conjugates
UBI29–41 was rstly conjugated to carboxyuorescein (UBI-1)
and used to image bacteria with analysis via confocal
microscopy. This yielded insuﬃcient signal to noise to
distinguish bacteria from background uorescence (Fig. 1).
We therefore took advantage of the environmental reporting
properties of the uorophore 7-nitrobenz-2-oxa-1,3-diazole
(NBD)12 and hypothesized there would be uorescence
amplication of NBD in the apolar hydrophobic bacterial
membrane. UBI-2 demonstrated good signal to noise and was
able to detect bacteria (Fig. 1).Removing and replacing the methionine residue improves
stability
UBI-2 underwent chemical degradation upon storage in phos-
phate buﬀered saline at 37 C, which was prevented by substi-
tution of the Met to Nle, giving rise to UBI-3 (Fig. 2). This
modication is particularly of relevance due to the expected in
vivo inammatory oxidative environment within an infectedFig. 5 Sites of structural modiﬁcations undertaken on UBI-3 based on M
This journal is © The Royal Society of Chemistry 2015pneumonic lung due to inltrating host inammatory cells
such as neutrophils,13 and therefore all subsequent modica-
tions incorporated Nle in place of Met.
To assess the bacterial labelling consequences of this single
amino acid substitution, UBI-2 and UBI-3 were screened against
a panel of Gram positive (methicillin-sensitive Staphylococcus
aureus (MSSA)) and Gram negative pathogenic bacteria (Pseu-
domonas aeruginosa and Klebsiella pneumoniae) demonstrating
retained bacterial labelling with specicity over eukaryotic cells
(Fig. 3).ALDI-TOF analysis of proteolytic degradation.
Chem. Sci.
Chemical Science Edge Article
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View Article OnlineControlling degradation in human bronchoalveolar lavage
uid (BALF)
To determine the ability of UBI-3 to image bacteria in the
continued presence of a complex inammatory environment,
bacteria were labelled with UBI-3 in the presence of broncho-
alveolar lavage uid (BALF) retrieved from ventilated ICU
patients with Acute Respiratory Distress Syndrome (ARDS).
ARDS BALF was utilised as ARDS is a severe life threatening
pulmonary syndrome, characterized by a massive proteolytic
and oxidative inammatory environment within the distalFig. 7 UBI-10 remains stable in ARDS BALF at 5 minutes. (A) Structure of U
a MALDI-TOF time course of UBI-10 in ARDS BALF, demonstrating initia
Chem. Sci.alveolar region.14 Under these harsh experimental condi-
tions, there was a signicant reduction in the uorescent
labelling intensity of bacteria with UBI-3 (Fig. 4). This was
due to the rapid (<5 min) degradation of the peptide as
demonstrated by Matrix-Assisted Laser Desorption/Ioniza-
tion Time-of-Flight Mass Spectrometry (MALDI-TOF MS)
analysis (ESI Fig. S1†). To design out susceptible amino acid
cleavage points, a number of modications were made (Table
1) and the functional consequences assessed. The chemical
approaches pursued to improve resistance to degradationBI-10 with breakdown products in ARDS BALF. The lower panel shows
l stability but the formation of degradation products after 10 minutes.
This journal is © The Royal Society of Chemistry 2015
Fig. 8 Confocal images and quantiﬁcation of cyclic variants when
compared to UBI-3. Panels showmethicillin-sensitive Staphylococcus
aureus incubated with cyclic UBI compounds (all 10 mM) with quan-
tiﬁcation of bacterial ﬂuorescence normalized to UBI-3 (bars represent
mean (SEM), n $ 3, ns ¼ not signiﬁcant, ** ¼ p < 0.01, scale bar ¼
10 mm).
Edge Article Chemical Science
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View Article Onlineincluded replacing amino acids at the cleavage positions with
non-natural amino acids such as N-methyl or D-amino
acids,15 and cyclisation of the peptide,16 which could have the
added benet of enhancing aﬃnity towards bacterial
membrane.17
Modication of mass spectrometry identied degradation
sites
The Arg–Arg bonds were identied as the prominent position of
degradation (Fig. 5) and Compounds UBI-4–9 (Table 1) were
synthesised with a variety of substitutions around the degra-
dation sites. The susceptible peptide bonds at P1–P2 and P7–P8
were blocked using N-MeArg (UBI-4), and to further mask these
positions, a long polyethylene glycol (PEG) chain and/or a
D-amino acid were positioned at the carboxylic and/or amino
termini (UBI-5–7). N-MeArg insertion (UBI-4) or N-MeArg with
two D-amino acid residues at the C-terminal (UBI-5) improved
stability in ARDS BALF (ESI Fig. S2†) and allowed bacterial
labelling at the same intensity as UBI-3 (Fig. 6). However,
insertion of a PEG chain at both termini (UBI-6) and constructs
with entirely D-amino acids (UBI-8 and UBI-9), whilst improving
stability, resulted in loss of labelling on bacteria (ESI Fig. S2 and
6†). A single PEG at the C-terminus alone (UBI-7) did not
improve stability in ARDS BALF, and resulted in loss of bacterial
labelling.
Cyclisation of the peptide sequence
We hypothesized that cyclisation of the sequence would allow
for greater stability and also improve bacterial aﬃnity and
therefore cyclic variants of UBI-3 were synthesized (UBI-10 and
UBI-11), which were both found to be stable in BALF for 5
minutes (Fig. 7 and S3 ESI†). Compared to the UBI-3 there was a
signicantly higher signal for equivalent concentrations of the
cyclic construct (UBI-10) (Fig. 8). However, these studies also
highlighted the degradation of UBI-10 at 10 minutes, guiding
the temporal constraints of Smartprobe delivery and optical
imaging. UBI-11 demonstrated that a single amino acid change
imparted stability in BALF for over 30 minutes and the
compound showed comparable bacterial labelling to UBI-3, (ESI
Fig. S3†) however the enhanced bacterial labelling seen with
UBI-10 was lost (Fig. 8).
Bacterial aﬃnity evaluation
Three compounds (UBI-3, UBI-5 and UBI-10) were assessed for
further evaluation. The rationale for assessing these variants
was that UBI-3 and UBI-10 were native UBI sequences in linear
or cyclic secondary structures respectively and UBI-5 was
stable and demonstrated a similar bacterial labelling to UBI-3.
Bacterial labelling was demonstrated in a concentration
dependent manner for all three compounds. The relative
uorescence of UBI-10 labelled bacteria was higher than UBI-3
or UBI-5 labelled bacteria (Fig. 9). At 10 mM, UBI-10 retained
bacterial specicity over neutrophils. However at 50 mM, some
neutrophil labelling was observed (Fig. 9). In vitro aﬃnity of
bacterial binding was assessed by incorporating a wash step in
the live confocal imaging protocol with a panel of bacteria withThis journal is © The Royal Society of Chemistry 2015the ‘wash-oﬀ’ representing a surrogate indicator of Smartp-
robe-bacterial labelling aﬃnity. This demonstrated that
following labelling and a wash, there was signicantly lower
uorescence for the linear compounds (UBI-3 and UBI-5) than
the cyclic compound without modication (UBI-10) (ESI
Fig. S4†) against three diﬀerent bacterial species. UBI-10,
therefore, was assessed further in a clinically relevant biolog-
ical system.
Bacterial detection by a clinical bre-based optical imaging in
human lung tissue
Fibered confocal uorescence microscopy (FCFM) with a
488 nm laser system enables in vivo cellular and subcellular
resolution imaging deep in human lung.18 This system allows
imaging of the intrinsic autouorescence of elastin thereby
enabling alveolar imaging. Therefore, to assess whether this
platform has the resolution to detect uorescent bacteria, we
pre-labeled bacteria (with calcein AM) and then demonstrated
that we were able to detect uorescently labeled bacteria on
the background of human lung autouorescence (ESI
Fig. S5†).
Since NBD is also excited at 488 nm, the utility and detec-
tion of the Smartprobes with FCFM was next evaluated.
Bacteria were labelled with UBI-3 and UBI-10 and imaged in
suspension demonstrating the punctate uorescence pattern
of labelled bacteria. These were then delivered onto ex vivo
human lung tissue fragments. Bacteria labelled with UBI-3
immediately lost their uorescent signal whereas UBI-10Chem. Sci.
Fig. 9 UBI-3, UBI-4 and UBI-10 label bacteria in a concentration dependent manner. (A) UBI-3, UBI-4 and UBI-10 (0.5 mM to 50 mM) co-
incubated with methicillin sensitive S. aureus and imaged by confocal microscopy with quantiﬁcation of ﬂuorescence, demonstrating a
concentration dependent increase in bacterial ﬂuorescence. UBI-10 retains a higher ﬂuorescence (per molar equivalents) at all concen-
trations tested. Right panel shows representative images. (B) Representative images of a co-culture of isolated human neutrophils and
methicillin sensitive S. aureus and UBI-10 at 10 mM (upper panels) and at 50 mM (lower panels) demonstrating no labelling of neutrophils at 10
mM, however at 50 mM, occasional neutrophil labelling was observed (blue arrows).
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View Article Onlinelabelled bacteria, were readily identied above elastin auto-
uorescence (Fig. 10).
Summary
We synthesised a library of uorescently labelled UBI29–41
mimetic peptides for rapid, live, bacterial imaging; with the
ambition to develop Smartprobes that demonstrate potential
clinical utility in conditions of high unmet need; such as the
rapid diagnosis of suspected pneumonia in critically ill individ-
uals. We discovered key determinants of peptide stability and
bacterial binding aﬃnity as potential obstacles for clinical utility.
A number of structural modications were subsequently engi-
neered to drive improved stability, resistance to degradation and
improve function. A cyclic variant of NBD–UBI (UBI-10) proved to
be the most functional and specic Smartprobe for bacterial
detection and showed proof of concept for detection of bacteria
over intrinsic lung elastin autouorescence in human lung tissue.Chem. Sci.These ndings provide pivotal insights into future strategies
to develop chemical Smartprobes capable to detect bacteria
within the distal human lung.Acknowledgements
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Fig. 10 UBI-10 can be used to image bacteria in ex vivo human lung tissue by ﬁbered confocal ﬂuorescence microscopy (FCFM). FCFM imaging
of bacteria in suspension (upper panels) or when co-incubated with ex vivo human lung tissue (lower panels). Left images demonstrate no
intrinsic autoﬂuorescence of bacteria, middle panels showUBI-3 can image bacteria in suspension but not in the presence of ex vivo human lung
and right panels demonstrate UBI-10 can image bacteria by FCFM in the presence of ex vivo human lung with a characteristic small round,
punctate ﬂuorescence. All compounds at 10 mM, n ¼ 3.
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